SOURCE: OctoPlus N.V.

March 05, 2009 01:37 ET

OctoPlus Gives Update on Shareholdings Following Its Recent Fundraising

LEIDEN, NETHERLANDS--(Marketwire - March 5, 2009) - OctoPlus N.V. ("OctoPlus" or the "Company") (EURONEXT: OCTO) today publishes an updated overview of the shareholdings by its major investors and CEO, as a result of the fundraising that was concluded on 25 February.


Current shareholdings of OctoPlus' major investors:

--  Life Sciences Partners: 17.2%
--  S.R. One: 16.9%
--  Signet Healthcare Partners: 16.6%
--  Sodoro B.V., the personal holding company of Joost Holthuis, Chief
    Operating Officer of OctoPlus: 10.2%
--  Innoven Partenaires: 9.3%
--  Fagus: 7.2%
--  SurModics: 4.9%
    
    

The Company's CEO Simon Sturge has participated in the financing to the amount of 133,333 shares.

For further information, please contact:
Rianne Roukema, Corporate Communications:  telephone number +31  (71)
524 1071, e-mail IR@octoplus.nl.

About OctoPlus

OctoPlus is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The lead product incorporating our technology is Locteron®, a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, which has been licensed to Biolex Therapeutics and is being manufactured by OctoPlus. Locteron is currently in Phase II clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

Click here for the press release in PDF: http://hugin.info/137076/R/1295188/294021.pdf


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.

Contact Information